10 Recruiting Recurrent Acute Myeloid Leukemia Phase 1 Clinical Trials
Active phase 1 studies for recurrent acute myeloid leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Recurrent Acute Myeloid Leukemia studiesPhase 1 Studies for Recurrent Acute Myeloid Leukemia
🔵 Active, Not Recruiting Phase1
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
📍 Children's Hospital of Alabama — Birmingham, Alabama
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase1
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase1
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 Roswell Park Cancer Institute — Buffalo, New York
View Study & Checklist ➔ 🟢 Recruiting Phase1
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔ 🟢 Recruiting Phase1
Tazemetostat and Palbociclib With CPX-351for R/R AML
📍 Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
View Study & Checklist ➔